| Page 54 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Author(s): 
Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell P
Primary Author: 
Haase D
Journal Title: 
Leukemia
Original Publication Date: 
Jan 2019
Risk stratification is critical in the care of patients with
Bone Marrow Disease(s): 

Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes.

Author(s): 
Zeidan AM, Klink AJ, McGuire M, Feinberg B.
Primary Author: 
Zeidan AM
Journal Title: 
Leuk Lymphoma.
Original Publication Date: 
Jan 2019
Lenalidomide and hypomethylating agents (HMAs) azacitidine and decitabine are approved for treating
Bone Marrow Disease(s): 

Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes.

Author(s): 
Hamilton BK, Rybicki L, Hirsch C, Przychodzen B, Nazha A, Gerds AT, Hanna R, Kalaycio M, Sekeres MA, Sobecks R, de Lima M, Majhail NS, Maciejewski J.
Primary Author: 
Hamilton BK
Journal Title: 
Bone Marrow Transplant
Original Publication Date: 
Jan 2019
Next generation sequencing (NGS) has become an important tool to inform disease risk for myeloid malignancies, however data remains conflicting regarding the significance of individual mutations. We performed targeted NGS on 112 patients with AML, and 80 with MDS, who underwent allogeneic hematopoietic cell transplantation. The most common mutations in AML were TET2 (14.7%), FLT3 (12.9%), DNMT3A (12.1%), and RUNX1 (7.8%).
Bone Marrow Disease(s): 

Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant.

Author(s): 
Fozza C.
Primary Author: 
Fozza C.
Journal Title: 
Crit Rev Oncol Hematol
Original Publication Date: 
Jan 2019
Several findings suggest that the pathogenesis and clinical history of
Bone Marrow Disease(s): 

Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.

Author(s): 
Tang Y, Miao M, Han S, Qi J, Wang H, Ruan C, Wu D, Han Y.
Primary Author: 
Tang Y
Journal Title: 
Crit Rev Oncol Hematol
Original Publication Date: 
Jan 2019
SF3B1 gene mutations are the most frequent mutations found in
Bone Marrow Disease(s): 

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

Author(s): 
Sallman DA, List A
Primary Author: 
Sallman DA
Journal Title: 
Blood
Original Publication Date: 
Jan 2019
In cancer biology, tumor-promoting inflammation and an inflammatory microenvironment play a vital role in disease pathogenesis. In the past decade, aberrant innate immune activation and proinflammatory signaling within the malignant
Bone Marrow Disease(s):